u/rt_shift_reggie

that is the one from the ERP thread? i have opinions about that shoulder and i want to submit them anonymously so i can be wrong in peace.

my first guess was ghost peak from plumbing but a reproducible 0.9% that survives blank subtraction is too well behaved for that. plumbing ghosts wander.

if there is a chromatogram attached, post that too. the shape of the 3.2% tells you more than the size of it.

check who the comparator was before you compare anything

a shoulder that big is usually a des-amido form or an epimer and the integration decision on where to cut it changes your number by half a point on its own.

post the trace. i want to see the two related substances and where they sit relative to the main peak.

Yes — the interval is the finding.

Disagreeing with this line: that is a relative reduction and the absolute numbers are considerably less dramatic.

say which country or the thread is useless

Is the prescription from the same country as the pharmacy?

Not convinced. Cross-trial comparison between two programmes with different populations and designs is not a comparison.

Bought small deliberately because the evidence base is thin. That felt like the only defensible approach.

Relative risk reduction without the baseline rate is uninterpretable. A large relative reduction on a small absolute risk is a small absolute benefit.

Pharmacy pricing on a private prescription is set by the pharmacy. The spread between them in a given month is routinely substantial, which is why a tracker built from member reports is more useful than any headline.

Nothing on this board is medical advice, and the people answering you — including me — are members with spreadsheets rather than clinicians.

Took three weeks to understand titration and about ten seconds once somebody explained it as a tolerance ladder.

GP said no in the spring, specialist said yes eighteen months later. Same person, same numbers.

Right, and writing the concentration on the vial is the single best habit anyone here can start with.

The engineering problem was duration: native amylin is short-acting and aggregation-prone.

This is the distinction that keeps this board honest — different axis, not a stronger version of the same one.

Week 12 for me was completely flat and I was convinced something was wrong. It was not. Month two was where everything happened.

Cosigning on the thin independent data. Fewer members test this, so the bands are wider and should be treated that way.

That is an authorisation question and you have answered a reimbursement one.

hydration_hank is right about cross-border recognition being narrower than the summaries suggest.

Argued for a week about a result and then read the limitations section, which conceded most of my opponent’s point.

Open-label extensions lose their randomisation. Anybody still enrolled at week 104 is a selected group and the numbers describe that group.

Yes. The shortage list is the legal hinge for the whole arrangement and its status is public.

What does the wiki page on this say — genuinely asking, not deflecting?

Pharmacy pricing on a private prescription is set by the pharmacy. The spread between them in a given month is routinely substantial, which is why a tracker built from member reports is more useful than any headline.

Yes — four nations, four pathways, and threads that ignore that give people the wrong answer confidently.

Combination and monotherapy arms must be read separately. Efficacy and tolerability both differ substantially between them and summaries routinely blur the two.

Wrote the concentration on the vial after reading it here. Have never once had to reconstruct it from memory since.

What did the intake actually ask you?

Not convinced — the US threads are a different system entirely and importing their advice here does real harm.

That is the 68-week readout, not the 72-week one. Different trial, different duration.

Absolute or relative risk reduction?

Read a press release and the publication three months apart. The hedging in the second one was substantial.

Why the monthly pricing tracker works, and the rule that makes it work.

Members post the pharmacy, the product, the month and the price they actually paid — not an advertised offer, not a first-month discount. No links of any kind are permitted, which removes the entire incentive to post anything other than what happened.

The result is that the spread between pharmacies in a given month is visible, and it is consistently larger than people expect. That single table has saved members here more money than every other thread on the board combined, and it survives only because the no-links rule is enforced without exception.

That shortage notice was national and does not apply where the question is coming from.

Is this a cross-border question or a domestic one?

Pack sizes and presentations differ between member states, so a headline price is not comparable until it is normalised to a common quantity.

Agreed — and normalising pack size before comparing prices is the fix for half these threads.

That is a relative risk reduction. Quoting it without the absolute numbers overstates the case considerably.

no referral links, ever, and that rule is why the pricing threads work